A detailed history of Buckingham Strategic Wealth, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Buckingham Strategic Wealth, LLC holds 2,011 shares of VRTX stock, worth $907,423. This represents 0.01% of its overall portfolio holdings.

Number of Shares
2,011
Previous 1,782 12.85%
Holding current value
$907,423
Previous $744,000 26.61%
% of portfolio
0.01%
Previous 0.01%

Shares

27 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 12, 2024

BUY
$392.81 - $485.53 $89,953 - $111,186
229 Added 12.85%
2,011 $942,000
Q1 2024

May 09, 2024

BUY
$407.69 - $446.08 $8,561 - $9,367
21 Added 1.19%
1,782 $744,000
Q4 2023

Feb 14, 2024

BUY
$343.0 - $410.68 $86,093 - $103,080
251 Added 16.62%
1,761 $716,000
Q3 2023

Nov 13, 2023

BUY
$338.18 - $362.46 $25,025 - $26,822
74 Added 5.15%
1,510 $525,000
Q2 2023

Aug 11, 2023

BUY
$314.42 - $351.91 $49,992 - $55,953
159 Added 12.45%
1,436 $505,000
Q4 2022

Feb 13, 2023

SELL
$285.76 - $321.48 $8,287 - $9,322
-29 Reduced 2.22%
1,277 $368,000
Q3 2022

Nov 07, 2022

BUY
$273.83 - $305.53 $12,048 - $13,443
44 Added 3.49%
1,306 $378,000
Q2 2022

Aug 12, 2022

SELL
$234.96 - $292.55 $3,524 - $4,388
-15 Reduced 1.17%
1,262 $356,000
Q1 2022

May 10, 2022

BUY
$221.42 - $260.97 $11,513 - $13,570
52 Added 4.24%
1,277 $333,000
Q4 2021

Feb 09, 2022

SELL
$177.01 - $223.45 $1,416 - $1,787
-8 Reduced 0.65%
1,225 $269,000
Q3 2021

Nov 10, 2021

BUY
$181.39 - $202.99 $8,162 - $9,134
45 Added 3.79%
1,233 $224,000
Q2 2021

Aug 06, 2021

SELL
$187.49 - $221.1 $5,437 - $6,411
-29 Reduced 2.38%
1,188 $240,000
Q1 2021

Apr 30, 2021

SELL
$207.02 - $241.31 $35,400 - $41,264
-171 Reduced 12.32%
1,217 $262,000
Q4 2020

Feb 16, 2021

BUY
$207.01 - $276.09 $9,729 - $12,976
47 Added 3.5%
1,388 $328,000
Q3 2020

Nov 12, 2020

BUY
$255.65 - $303.1 $120,155 - $142,457
470 Added 53.96%
1,341 $365,000
Q2 2020

Aug 03, 2020

SELL
$225.48 - $295.8 $129,876 - $170,380
-576 Reduced 39.81%
871 $253,000
Q1 2020

May 07, 2020

SELL
$199.77 - $247.81 $69,120 - $85,742
-346 Reduced 19.3%
1,447 $344,000
Q4 2019

Feb 04, 2020

SELL
$166.71 - $223.91 $143,370 - $192,562
-860 Reduced 32.42%
1,793 $393,000
Q3 2019

Nov 12, 2019

SELL
$166.23 - $187.09 $134,147 - $150,981
-807 Reduced 23.32%
2,653 $449,000
Q2 2019

Aug 05, 2019

SELL
$164.61 - $190.37 $8,230 - $9,518
-50 Reduced 1.42%
3,460 $634,000
Q1 2019

May 02, 2019

BUY
$163.73 - $194.7 $216,287 - $257,198
1,321 Added 60.35%
3,510 $646,000
Q4 2018

Feb 11, 2019

SELL
$151.91 - $192.21 $10,329 - $13,070
-68 Reduced 3.01%
2,189 $363,000
Q3 2018

Nov 02, 2018

SELL
$167.73 - $192.74 $36,061 - $41,439
-215 Reduced 8.7%
2,257 $435,000
Q2 2018

Aug 13, 2018

BUY
$145.72 - $169.96 $76,357 - $89,059
524 Added 26.9%
2,472 $420,000
Q1 2018

May 14, 2018

SELL
$151.6 - $177.13 $30,320 - $35,426
-200 Reduced 9.31%
1,948 $317,000
Q4 2017

Feb 12, 2018

SELL
$137.28 - $155.55 $16,748 - $18,977
-122 Reduced 5.37%
2,148 $322,000
Q3 2017

Nov 08, 2017

BUY
$148.13 - $162.24 $336,255 - $368,284
2,270
2,270 $345,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $116B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Buckingham Strategic Wealth, LLC Portfolio

Follow Buckingham Strategic Wealth, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Buckingham Strategic Wealth, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Buckingham Strategic Wealth, LLC with notifications on news.